Angeion Reports Sales Success
in the Clinical Research Market

Commitment to this Market Yields New Agreements, Endorses
Company’s Technology, Products, Clinical Expertise and Customer Support

SAINT PAUL, Minn. (March 22, 2006) — Angeion Corporation (NASDAQ CM: ANGN) announced today that efforts to extend and enhance its commitment to sell and market MedGraphics’ non-invasive cardiorespiratory diagnostic systems to the clinical device and drug trial research market are having significant results.  These results include the recent execution of new agreements under which the Company will supply its diagnostic systems and services to third parties conducting clinical studies.  Angeion believes sales to these third parties for clinical studies have the potential to result in revenue increases approaching 5-10% of Angeion’s MedGraphics cardiorespiratory products.  Terms of the recent agreements are confidential.

“When you consider the critical importance and large development expenditures required of pharmaceutical and medical device companies to bring a drug or a device safely to market, the clinical research opportunity is sizeable for us,” remarked Rodney A. Young, President and Chief Executive Officer of Angeion Corporation.  “For a number of years, we have established ourselves in clinical trials by documenting product safety and validating efficacy.  Our reputation for high-quality products, applications know-how, exceptionally reliable and consistent performance, and industry-leading technical service and customer support in the hospital and physician markets well-positions Medical Graphics to successfully participate in this growing market segment.  

“We feel fortunate to have earned the distinction of working with these new partners, whose commitment to patient safety, product quality and effectiveness is unparalleled in the industry.  In terms of revenue, these new agreements represent the largest clinical research relationships that we have entered into to date.  As a result, we should experience upside to revenue, cash flow and gross margins.  We view these new partnerships as notable recognition of our Medical Graphics’ products, clinical and technical expertise, and our customer service,” concluded Young.

About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics (www.medgraphics.com) in December 1999.  Medical Graphics develops, manufactures and markets non-invasive diagnostic systems for the management and improvement of cardiorespiratory health.  These products are sold internationally through distributors and in the United States through a direct sales force that targets customers located in hospitals, university-based medical centers, clinics and physician offices of heart and lung specialists.  The Company also sells a line of health and fitness products, many of which are derived from MedGraphics’ cardiorespiratory product technologies.  These products, marketed under the New Leaf health and fitness brand (www.newleaffitness.com), help consumers effectively manage their weight, improve fitness, or enhance athletic performance.  They are marketed to the consumer primarily through personal training studios, health and fitness clubs and other exercise facilities.  For more information about Angeion, visit www.angeion.com. 

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements by their nature involve substantial risks and uncertainties.  Actual results may differ materially depending on a variety of factors, including (i) the Company’s ability to successfully operate its Medical Graphics business including, its ability to develop, improve and update its cardiorespiratory diagnostic products, (ii) the Company’s ability to successfully sell its New Leaf health & fitness products, (iii) the Company’s ability to successfully defend itself from product liability claims related to its Medical Graphics’ products and claims associated with its prior cardiac stimulation products, (iv) the Company's ability to successfully resolve all issues in connection with the lawsuit with Medmarc over the Company’s ICD product liability insurance coverage; (v) the Company’s ability to protect its intellectual property, and (vi) the Company’s dependence on third-party vendors.  Additional information with respect to the risks and uncertainties faced by the Company may be found in, and any prior discussion is qualified in its entirety by, the other risk factors that are described from time to time in Angeion's Securities and Exchange Commission reports, including but not limited to the Annual Report on Form 10-KSB for the year ended October 31, 2005, and subsequently filed reports.

# # #